## Hepatotoxicity Mechanisms in First-Line Antitubercular Drugs ### Overview of TB Drug-Induced Liver Injury **Key Point:** All first-line TB drugs carry hepatotoxicity risk, but the mechanisms differ. The question asks which drug is **best distinguished** by its hepatotoxicity mechanism — and Isoniazid (INH) stands out due to its **acetylation-dependent metabolic idiosyncrasy** in slow acetylators. ### Isoniazid: The Classically Distinguished Mechanism **High-Yield:** INH is metabolized by N-acetyltransferase 2 (NAT2) to acetyl-isoniazid, which is further hydrolyzed to acetylhydrazine and hydrazine — the primary hepatotoxic metabolites. In **slow acetylators**, acetylhydrazine accumulates and undergoes CYP2E1-mediated oxidation to reactive intermediates that cause hepatocellular necrosis. **Clinical Pearl:** INH hepatotoxicity is: - **Idiosyncratic** but with a clear pharmacogenomic basis (NAT2 slow acetylator phenotype) - More common in **slow acetylators** (higher accumulation of hydrazine derivatives) - **Potentiated by rifampicin** (CYP2E1 induction increases toxic metabolite formation) - Risk increases with **age >35 years**, alcohol use, and pre-existing liver disease This mechanism is uniquely tied to a **specific metabolic pathway (acetylation)** and a **pharmacogenomic risk factor**, making it the most mechanistically distinctive among the four options. ### Why the Other Options Are Incorrect **Pyrazinamide (Option B):** The claim that PZA causes hepatotoxicity via "hyperuricemia and uric acid precipitation" is a **factual error**. Hyperuricemia is a side effect of PZA (due to inhibition of renal tubular urate secretion by pyrazinoic acid), but it does **not** cause liver injury. PZA hepatotoxicity is actually **idiosyncratic and dose-dependent**, mediated by toxic metabolites (pyrazinoic acid and 5-hydroxypyrazinoic acid) causing direct hepatocellular damage — a mechanism not fundamentally different from INH. *(KD Tripathi, Essentials of Medical Pharmacology, 8th ed.)* **Rifampicin (Option C):** RIF causes hepatotoxicity via enzyme induction (CYP450 auto-induction) and formation of desacetylrifampicin. However, RIF alone is rarely hepatotoxic; its major role is **potentiating INH hepatotoxicity** by inducing CYP2E1. This is not a uniquely distinguishing mechanism. **Ethambutol (Option D):** EMB is the **least hepatotoxic** first-line drug. Hepatotoxicity from EMB is exceedingly rare, and the description of "direct hepatocellular injury independent of metabolism" is not well-supported in standard pharmacology texts. EMB is primarily associated with **optic neuritis**, not liver injury. ### Comparison Table | Drug | Mechanism | Type | Pharmacogenomic Basis | Key Risk Factor | | --- | --- | --- | --- | --- | | **Isoniazid** | Acetylation → hydrazine → reactive intermediates | Idiosyncratic (metabolic) | **Yes (NAT2 slow acetylators)** | Slow acetylator, age >35 | | **Rifampicin** | CYP induction → toxic metabolites | Idiosyncratic | No | Combined with INH | | **Pyrazinamide** | Toxic metabolites (pyrazinoic acid) | Idiosyncratic/dose-dependent | No | High dose, renal impairment | | **Ethambutol** | Rare; mechanism unclear | Direct (rare) | No | Pre-existing liver disease | ### Why Option A is Correct Isoniazid is **best distinguished** because: 1. Its hepatotoxicity has a **well-defined pharmacogenomic basis** (NAT2 slow acetylator status). 2. The mechanism — **acetylation-dependent accumulation of hydrazine metabolites** — is unique among first-line TB drugs. 3. It is the **most common cause** of anti-TB drug-induced liver injury. 4. The mechanism is textbook-classic and directly testable in NEET PG/INI-CET. [cite: KD Tripathi, Essentials of Medical Pharmacology, 8th ed., Ch. 45; Harrison's Principles of Internal Medicine, 21e, Ch. 157]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.